Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Treasury Shares (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Treasury Shares for 7 consecutive years, with $69486.0 as the latest value for Q4 2025.

  • On a quarterly basis, Treasury Shares rose 61.33% to $69486.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $69486.0, a 61.33% increase, with the full-year FY2025 number at $69486.0, up 61.33% from a year prior.
  • Treasury Shares was $69486.0 for Q4 2025 at Fulcrum Therapeutics, down from $69.5 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $70.7 million in Q2 2025 to a low of $536.0 in Q3 2021.
  • A 5-year average of $9.4 million and a median of $76718.0 in 2022 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: tumbled 88.3% in 2021, then soared 97577.75% in 2025.
  • Fulcrum Therapeutics' Treasury Shares stood at $536.0 in 2021, then skyrocketed by 14213.06% to $76718.0 in 2022, then fell by 2.22% to $75017.0 in 2023, then crashed by 42.58% to $43072.0 in 2024, then surged by 61.33% to $69486.0 in 2025.
  • Per Business Quant, the three most recent readings for FULC's Treasury Shares are $69486.0 (Q4 2025), $69.5 million (Q3 2025), and $70.7 million (Q2 2025).